Agile Therapeutics (Princeton, New Jersey) reported new results from a Phase III pivotal trial of AG200-15 (the Agile Patch), the company's once-weekly low-dose combination birth control patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). The data were presented yesterday at the American College of Obstetricians and Gynecologists' (ACOG; Washington) 60th annual clinical meeting in San Diego. Read More
